Tempus AI与第一三共株式会社宣布达成战略合作,旨在利用人工智能技术推进抗体偶联药物(ADC)临床项目中的生物标志物发现与临床差异化研究。根据合作协议,第一三共将采用Tempus自主研发的基础模型及AI技术专长,其中包括PRISM2多模态基础模型,以加速肿瘤治疗领域的创新突破。
Tempus AI与第一三共株式会社宣布达成战略合作,旨在利用人工智能技术推进抗体偶联药物(ADC)临床项目中的生物标志物发现与临床差异化研究。根据合作协议,第一三共将采用Tempus自主研发的基础模型及AI技术专长,其中包括PRISM2多模态基础模型,以加速肿瘤治疗领域的创新突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.